Skin of Color

An Open Label Study of Clobetasol Propionate 0.05% and Betamethasone Valerate 0.12% Foams in the Treatment of Mild to Moderate Acne Keloidalis

Author and Disclosure Information

Acne keloidalis (AK) is a disease affecting primarily African American men. Topical steroids are a widely accepted treatment of AK; however, no studies have been published investigating their effectiveness. The purpose of this open-label study was to assess the efficacy and tolerability of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of AK in 20 African American patients. These patients were treated for 8 to 12 weeks using a pulsed-dose regimen. We found topical clobetasol propionate foam to be effective in improving AK, and our patients found the foam vehicle to be cosmetically acceptable.


 

Recommended Reading

Atrophic Acne Scars Improved With Nd: YAG Laser
MDedge Dermatology
Consider Phototherapy as an Alternative Acne Treatment
MDedge Dermatology
Lasers' Effect on Acne Linked to Increased Cytokine
MDedge Dermatology
The Changing Face of Acne [editorial]
MDedge Dermatology
The Pathophysiology of Acne Vulgaris in Children and Adolescents, Part 1
MDedge Dermatology
A Status Report on the Use of Subantimicrobial-Dose Doxycycline: A Review of the Biologic and Antimicrobial Effects of the Tetracyclines
MDedge Dermatology
The Pathophysiology of Acne Vulgaris in Children and Adolescents, Part 2: Tailoring Treatment
MDedge Dermatology
Getting SMARTer? [editorial]
MDedge Dermatology
Cumulative Irritation Potential of Adapalene 0.1% Cream and Gel Compared With Tretinoin Microsphere 0.04% and 0.1%
MDedge Dermatology
Cumulative Irritation Potential of Adapalene 0.1% Cream and Gel Compared With Tazarotene Cream 0.05% and 0.1%
MDedge Dermatology